Person: GÜNEŞ BAYIR, AYŞE
6 results
Search Results
Now showing 1 - 6 of 6
Publication Metadata only Thermal and Biochemical Effects of Low Level Electromagnetic Radiation on Rat Brains and Bodies(2014-06-01) KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; MAYADAĞLI, ALPASLAN; GÜNEŞ BAYIR, AYŞE; YAGCI, B; TAŞPINAR, ÖZGÜR; AYDIN, TEOMAN; TRABZON, M; KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; MAYADAĞLI, ALPASLAN; GÜNEŞ BAYIR, AYŞE; AYDIN, TEOMANPublication Metadata only Pain management with Radiotherapy and ozone with high dose vitamin C therapy in a case of bone metastatis of breast cancer patient(2018-02-01) KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; YILMAZ, RABİYE; GÜNEŞ BAYIR, AYŞE; BAŞIBÜYÜK, MERYEM; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; ŞİMŞEK, MUHARREM; KIZILTEPE, AYŞE; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; AYDOĞDU, İBRAHİM; ALTINOK SÜT, PELİN; AYDIN, TEOMAN; KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; GÜNEŞ BAYIR, AYŞE; BAŞIBÜYÜK, MERYEM; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; AYDOĞDU, İBRAHİM; ALTINOK SÜT, PELİN; AYDIN, TEOMANPublication Open Access Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study(2014-01-01) Kiziltan, HURİYE ŞENAY; Bayir, Ayse Gunes; TAŞTEKİN, Didem; Coban, GANİME; Eris, ALİ HİKMET; Aydin, TEOMAN; MAYADAGLI, Alparslan; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ÇOBAN, GANİME; ERİŞ, ALİ HİKMET; AYDIN, TEOMAN; MAYADAĞLI, ALPASLANBackground: Lung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. Materials and Methods: Ten patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at 6mg/m2 daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose. Results: Complete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20 %. Median survival time was 7 months. Conclusions: Median survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features.Publication Metadata only Medical ozone and radiotherapy in a peritoneal, erlich-ascites, tumor-cell model(2015-01-01) KIZILTAN, HURİYE ŞENAY; BAYIR, Ayşe Güneş; Yucesan, GÜL; Eris, ALİ HİKMET; KARATOPRAK, CUMALİ; İDİN, Kadir; AYDIN, TEOMAN; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; YÜCESAN, GÜL; ERİŞ, ALİ HİKMET; KARATOPRAK, CUMALİ; AYDIN, TEOMAN; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLANPublication Metadata only Successfull Pain Management with Radiotherapy and Ozone Therapy in a Case of Metastatic, Chemotherapy Resistant Sino-Nasal Mucosal Malignant Melanoma(2017-03-01) KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ERİŞ, ALİ HİKMET; BAŞIBÜYÜK, MERYEM; MAYADAĞLI, ALPASLAN; AKÇAKAYA, ADEM; ÇAKIR, FATMA BETÜL; AYDIN, TEOMAN; GÜL, KÜRŞAT; KARABAL, ESRA; ŞİMŞEK, MUHARREM; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ERİŞ, ALİ HİKMET; BAŞIBÜYÜK, MERYEM; MAYADAĞLI, ALPASLAN; AKÇAKAYA, ADEM; ÇAKIR, FATMA BETÜL; AYDIN, TEOMAN; GÜL, KÜRŞAT; KARABAL, ESRAPublication Metadata only Radioprotectant and Cytotoxic Effects of Spirulina in Relapsed Verrucous Vulvar Cancer: A Case Report(2015-01-01) Kiziltan, HURİYE ŞENAY; Bayir, Ayse Gunes; TAŞPINAR, Ozgur; Yucesan, GÜL; Tastekin, Didem; SONMEZ, Fatma Cavidan; Coban, GANİME; Kilic, GÖKHAN; Eris, ALİ HİKMET; Aydin, TEOMAN; Akcakaya, ADEM; Mayadagli, ALPASLAN; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; YÜCESAN, GÜL; ÇOBAN, GANİME; KILIC, GÖKHAN; ERİŞ, ALİ HİKMET; AYDIN, TEOMAN; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLANContext . The treatment of relapsed verrucous vulvar cancer (VVC) is difficult. When vulvar cancer relapses, the treatment response is low for second-line treatments. Conversely, toxicity is high. Therefore, scientists need to identify different treatment methods.